SCHEDULE: Sabby Management Discloses 9.9% Stake in Lyra Therapeutics
Beneficial Ownership Disclosure
Sabby Management, LLC and affiliated entities reported a 9.9% beneficial ownership stake in Lyra Therapeutics, Inc. common stock.
Summary
- Sabby Management, LLC, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. collectively reported beneficial ownership of 175,158 shares of Lyra Therapeutics, Inc. common stock.
- This ownership represents 9.87% of the class of securities.
- The reporting persons hold shared voting power and shared dispositive power over all 175,158 shares.
- The filing is a Schedule 13G, indicating a passive investment intent, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a neutral disclosure of beneficial ownership. The presence of a significant institutional investor can be seen as a mild positive, but the filing itself contains no performance or operational data.
Positives
- A significant institutional investor, Sabby Management, LLC, has taken a 9.87% stake in Lyra Therapeutics, Inc., which may signal confidence in the company's future prospects.
Negatives
- No specific negative information is disclosed in this Schedule 13G filing.
Risks
- No specific risks related to Lyra Therapeutics, Inc. are mentioned in this Schedule 13G filing.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Lyra Therapeutics, Inc.'s future outlook.
Industry Context
This Schedule 13G filing indicates an institutional investor's significant stake in a biotechnology company, which is a common occurrence in the sector as funds identify potential growth opportunities. It does not provide broader industry trend analysis.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor sentiment and potentially the stock price.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires the filing of this statement. |
| 01/20/2026 | Signature date for Sabby Management, LLC, Hal Mintz, and Sabby Volatility Warrant Master Fund, Ltd. |
Keywords
Lyra Therapeutics, Sabby Management, Hal Mintz, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.